Claims for Patent: 12,233,067

Summary for Patent: 12,233,067

Title:	Topical treatment of vitiligo by a JAK inhibitor
Abstract:	The present disclosure relates to topical treatment of vitiligo using ruxolitinib, or a pharmaceutically acceptable salt thereof.
Inventor(s):	Kathleen BUTLER, Jim Lee, Kang Sun, Fiona KUO, Michael Howell
Assignee:	Incyte Corp , Charter Communications Operating LLC
Application Number:	US18/077,315
Patent Claims:	1. A method of treating nonsegmental vitiligo in a patient, comprising: topically administering to a depigmented skin area of the patient a pharmaceutical composition comprising about 1.5% w/w ruxolitinib, or a pharmaceutically acceptable salt thereof, on a free base basis, twice per day; wherein: the patient suffers from nonsegmental vitiligo with depigmented area of: (i) 0.5% or greater body surface area (BSA) on the face, (ii) 3% or greater BSA on non-facial areas, and (iii) not exceeding 10% BSA on total body area; and the patient achieves a 75% or greater improvement in total body Vitiligo Area Scoring Index (T-VASI75). 2. The method of claim 1, wherein the method does not comprise administering laser or phototherapy. 3. The method of claim 1, wherein the ruxolitinib, or the pharmaceutically acceptable salt thereof, is ruxolitinib phosphate. 4. The method of claim 1, wherein topically administering is for at least 24 weeks. 5. The method of claim 4, wherein the patient achieves a 75% or greater improvement in T-VASI75 at week 24. 6. The method of claim 1, wherein the administering is for at least 52 weeks. 7. The method of claim 6, wherein the patient achieves a 75% or greater improvement in T-VASI75 at week 52. 8. The method of claim 1, wherein the patient has been clinically diagnosed with vitiligo. 9. The method of claim 1, wherein the patient is aged 12 years or older. 10. The method of claim 1, wherein the pharmaceutical composition is an oil-in-water emulsion, which is a cream. 11. The method of claim 1, wherein topically administering is continued until the patient achieves a 75% or greater improvement in facial Vitiligo Area Scoring Index after 24 weeks of the administering. 12. The method of claim 1, wherein topically administering is continued until the patient achieves a 90% or greater improvement in facial Vitiligo Area Scoring Index after 24 weeks of the administering. 13. The method of claim 1, wherein topically administering is continued until the patient achieves a 75% or greater improvement in facial Vitiligo Area Scoring Index after 52 weeks of the administering. 14. The method of claim 1, wherein topically administering is continued until the patient achieves a 90% or greater improvement in facial Vitiligo Area Scoring Index after 52 weeks of the administering. 15. The method of claim 1, wherein the pharmaceutical composition is administered to a patient population.